摘要
目的观察』匕嗽散加味颗粒剂联合信必可治疗咳嗽变异性哮喘的疗效。方法120例咳嗽变异性哮喘患者，采用完全随机分组法分为两组各60例。对照组采用信必可布地奈德福英特罗粉吸入剂吸入治疗，治疗组在对照组治疗基础上联用止嗽散加味颗粒剂治疗。结果治疗显效率为83．3％，优于对照组的70．0％（P〈0．05）。两组患者经治疗后，咳嗽、咽痒、气急、咯痰均明显好转，且治疗组优于对照组（，值分别为7．46、7．86、8．41，9．35，P均〈O．05）。肺功能第1秒用力呼气容积（forced expiratory volume in one second，FEVl）、FEV％和呼气峰流速（PEF）均有改善，治疗组治疗前后比较差异有统计学意义（t=2．351，P〈0．05）；治疗后组问比较差异有统计学意义（t=2．452，P〈0．05）；两组治疗后外周血EOS、ECP、IL．5均降低（t=4．952，P〈0．01），治疗组对ECP和IL-5的改善优于对照组（t=3．936，P〈0．01）。结论止嗽散加味颗粒剂联合信必可治疗咳嗽变异性哮喘有效。
Objective To observe the clinical effect of modified Zhisou powder and Symbicort Turbuhaler simultaneously on patients with Cough Variant Asthma. Methods 120 patients with Cough Variant Asthma were randomly recurited into two groups. 60 patients in the treatment group were treated with modified Zhisou powder and Symbicort Turbuhaler; 60 patients in the control group were treated with Symbicort Turbuhaler. 4 weeks was a therapeutic course in both group. Results The markedly controlled rate （MCR） （clinical control＋excenence）of the treatment group was 83.3%, obviously surpassed the control group （70.0%） （P〈0.05） ; There was obvious improvement of cough, expectoration, breath lessness and throaty pruritus after the therapy in both groups, but it was much better in the treatment group than the control group （P〈0.05）. The pulmonary function was significantly improved after treatment in both groups （FEV1, FEV1% and PEF, P〈 0.05）. The improvement showed significant difference between the two groups （P〈0.05）. There was obvious decrease ofEOS, IL-5 and ECP in both groups. The decrease of ECP and IL-5 in the treatment group was greater than the control group（P〈0.01）. Conclusion The therapy of modified Zhisou powder and Symbicort Turbuhaler has advantage over pure western therapy.
出处
《国际中医中药杂志》
2011年第6期487-490,共4页
International Journal of Traditional Chinese Medicine
关键词
咳嗽变异性哮喘
止嗽散加味:信必可
Cough variant asthma
Modified Zhisou powder
Symbicortturbuhaler
